Chemerin is a key adipokine—a signaling protein released by adipose tissue—that regulates lipid metabolism and insulin sensitivity and thus is involved in many metabolic diseases such as obesity and ...
Orphan nuclear receptors influence the onset and progression of MASLD, particularly in lipid metabolism, inflammation, autophagy, and cholesterol metabolism. These receptors may play either similar or ...
GLP-1 receptor agonists improve outcomes in patients with coronary plaque and post-STEMI, reducing adverse cardiovascular events and hospitalizations. Patients using GLP-1s show higher event-free ...
OrsoBio, Inc. (“OrsoBio” or “the Company”), a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced the publication in Nature ...
GAITHERSBURG, Md., June 22, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today presented data on the effect of pemvidutide, its GLP-1/glucagon ...
OrsoBio, a clinical-stage biopharmaceutical company developing treatments for obesity and related metabolic disorders, today announced positive topline results from a Phase 2a proof-of-concept study ...
Habegger is a professor in the UAB Department of Medicine Division of Endocrinology, Diabetes and Metabolism and also a scientist in the UAB Nutrition Obesity Research Center who studies how glucagon ...
Chemerin is a key adipokine that regulates lipid metabolism and insulin sensitivity, and thus is involved in many metabolic diseases such as obesity and diabetes. In addition, it plays a critical role ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results